journal
MENU ▼
Read by QxMD icon Read
search

Clinical Journal of the American Society of Nephrology: CJASN

journal
https://www.readbyqxmd.com/read/28923834/is-chronic-dialysis-the-right-hard-renal-end-point-to-evaluate-renoprotective-drug-effects
#1
Misghina Weldegiorgis, Dick de Zeeuw, Jamie P Dwyer, Peter Mol, Hiddo J L Heerspink
BACKGROUND AND OBJECTIVES: RRT and doubling of serum creatinine are considered the objective hard end points in nephrology intervention trials. Because both are assumed to reflect changes in the filtration capacity of the kidney, drug effects, if present, are attributed to kidney protection. However, decisions to start RRT are not only on the basis of filtration capacity of the kidney, but also on other factors. We therefore compared the time to RRT with the time to a fixed eGFR threshold and assessed the effect of the renoprotective drug irbesartan on both components...
September 18, 2017: Clinical Journal of the American Society of Nephrology: CJASN
https://www.readbyqxmd.com/read/28923833/nephrology-provider-prognostic-perceptions-and-care-delivered-to-older-adults-with-advanced-kidney-disease
#2
Huzaifah Salat, Andrei Javier, Edward D Siew, Rocio Figueroa, Loren Lipworth, Edmond Kabagambe, Aihua Bian, Thomas G Stewart, Maie H El-Sourady, Mohana Karlekar, Cesar Y Cardona, T Alp Ikizler, Khaled Abdel-Kader
BACKGROUND AND OBJECTIVES: Prognostic uncertainty is one barrier that impedes providers in engaging patients with CKD in shared decision making and advance care planning. The surprise question has been shown to identify patients at increased risk of dying. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: In our prospective observational study, 488 patients ≥60 years of age with CKD stage 4 or 5 were enrolled. Binary surprise question (i.e., "Would you be surprised if this patient died in the next 12 months?") responses were recorded, and dialysis planning preferences, presence of advance care planning documentation, and care preceding death were abstracted...
September 18, 2017: Clinical Journal of the American Society of Nephrology: CJASN
https://www.readbyqxmd.com/read/28923832/rethinking-end-points-in-clinical-trials-of-renoprotective-medication
#3
EDITORIAL
Aliza Thompson
No abstract text is available yet for this article.
September 18, 2017: Clinical Journal of the American Society of Nephrology: CJASN
https://www.readbyqxmd.com/read/28923831/international-comparisons-of-prevalence-awareness-and-treatment-of-pruritus-in-people-on-hemodialysis
#4
Hugh C Rayner, Maria Larkina, Mia Wang, Matthew Graham-Brown, Sabine N van der Veer, Tevfik Ecder, Takeshi Hasegawa, Werner Kleophas, Brian A Bieber, Francesca Tentori, Bruce M Robinson, Ronald L Pisoni
BACKGROUND AND OBJECTIVES: Uremic pruritus in patients on hemodialysis is associated with depression, lower quality of life, and mortality. We studied the prevalence, awareness, and treatment of pruritus to assess how well this important condition is currently managed internationally. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Data from 35,452 patients on hemodialysis in up to 17 countries from the Dialysis Outcomes and Practice Patterns Study were analyzed to describe pruritus prevalence from 1996 to 2015...
September 18, 2017: Clinical Journal of the American Society of Nephrology: CJASN
https://www.readbyqxmd.com/read/28912248/multi-disciplinary-vascular-access-care-and-access-outcomes-in-people-starting-hemodialysis-therapy
#5
Simardeep Gill, Robert Quinn, Matthew Oliver, Fareed Kamar, Rameez Kabani, Daniel Devoe, Priyanka Mysore, Neesh Pannu, Jennifer MacRae, Braden Manns, Brenda Hemmelgarn, Matthew James, Marcello Tonelli, Adriane Lewin, Ping Liu, Pietro Ravani
BACKGROUND AND OBJECTIVES: Fistulas, the preferred form of hemodialysis access, are difficult to establish and maintain. We examined the effect of a multidisciplinary vascular access team, including nurses, surgeons, and radiologists, on the probability of using a fistula catheter-free, and rates of access-related procedures in incident patients receiving hemodialysis. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We examined vascular access outcomes in the first year of hemodialysis treatment before (2004-2005, preteam period) and after the implementation of an access team (2006-2008, early-team period; 2009-2011, late-team period) in the Calgary Health Region, Canada...
September 14, 2017: Clinical Journal of the American Society of Nephrology: CJASN
https://www.readbyqxmd.com/read/28903970/urinary-fibrinogen-as-a-predictor-of-progression-of-ckd
#6
Hongtian Wang, Chunxia Zheng, Yinghui Lu, Qi Jiang, Ru Yin, Ping Zhu, Minlin Zhou, Zhihong Liu
BACKGROUND AND OBJECTIVES: Fibrinogen has been reported to be involved in kidney tubulointerstitial fibrosis and podocyte injury in mouse models. However, the relationship between urinary fibrinogen and kidney outcomes has not been clarified in patients with CKD. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We evaluated 402 patients with CKD and kidney biopsies, including 101 with diabetic nephropathy, 94 with idiopathic membranous nephropathy, 55 with idiopathic FSGS, and 152 with IgA nephropathy...
September 13, 2017: Clinical Journal of the American Society of Nephrology: CJASN
https://www.readbyqxmd.com/read/28893925/approaches-to-and-clinical-benefits-of-reducing-dietary-k-in-ckd
#7
EDITORIAL
Jessica Kendrick, Stuart Linas
No abstract text is available yet for this article.
September 11, 2017: Clinical Journal of the American Society of Nephrology: CJASN
https://www.readbyqxmd.com/read/28893924/changes-in-albuminuria-and-subsequent-risk-of-incident-kidney-disease
#8
Keiichi Sumida, Miklos Z Molnar, Praveen K Potukuchi, Koshy George, Fridtjof Thomas, Jun Ling Lu, Kunihiro Yamagata, Kamyar Kalantar-Zadeh, Csaba P Kovesdy
BACKGROUND AND OBJECTIVES: Albuminuria is a robust predictor of CKD progression. However, little is known about the associations of changes in albuminuria with the risk of kidney events outside the settings of clinical trials. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: In a nationwide cohort of 56,946 United States veterans with an eGFR≥60 ml/min per 1.73 m(2), we examined the associations of 1-year fold changes in albuminuria with subsequent incident CKD (>25% decrease in eGFR reaching <60 ml/min per 1...
September 11, 2017: Clinical Journal of the American Society of Nephrology: CJASN
https://www.readbyqxmd.com/read/28893923/drug-induced-acute-interstitial-nephritis
#9
Dennis G Moledina, Mark A Perazella
No abstract text is available yet for this article.
September 11, 2017: Clinical Journal of the American Society of Nephrology: CJASN
https://www.readbyqxmd.com/read/28893922/challenges-in-developing-new-therapies-for-vascular-access-dysfunction
#10
Karl A Nath, Michael Allon
No abstract text is available yet for this article.
September 11, 2017: Clinical Journal of the American Society of Nephrology: CJASN
https://www.readbyqxmd.com/read/28893921/randomized-controlled-trial-of-the-effect-of-dietary-potassium-restriction-on-nerve-function-in-ckd
#11
Ria Arnold, Timothy J Pianta, Bruce A Pussell, Adrienne Kirby, Kate O'Brien, Karen Sullivan, Margaret Holyday, Christine Cormack, Matthew C Kiernan, Arun V Krishnan
BACKGROUND AND OBJECTIVES: Neuromuscular complications are almost universal in CKD by the time that a patient commences dialysis. Recent studies have indicated that chronic hyperkalemia may contribute to the development of neuropathy in CKD. This study was undertaken to determine whether dietary restriction of potassium intake may be a neuroprotective factor in CKD. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: A 24-month prospective, single-blind, randomized, controlled trial was undertaken in 47 consecutively recruited patients with stages 3 and 4 CKD...
September 11, 2017: Clinical Journal of the American Society of Nephrology: CJASN
https://www.readbyqxmd.com/read/28893920/are-sgl2-inhibitors-ready-for-prime-time-for-ckd
#12
Roberto Pecoits-Filho, Vlado Perkovic
No abstract text is available yet for this article.
September 11, 2017: Clinical Journal of the American Society of Nephrology: CJASN
https://www.readbyqxmd.com/read/28882857/effect-of-sofosbuvir-based-hepatitis-c-virus-therapy-on-kidney-function-in-patients-with-ckd
#13
Meghan E Sise, Elke Backman, Guillermo A Ortiz, Gregory L Hundemer, Nneka N Ufere, Donald F Chute, Joseph Brancale, Dihua Xu, Jessica Wisocky, Ming V Lin, Arthur Y Kim, Ravi Thadhani, Raymond T Chung
BACKGROUND AND OBJECTIVES: Hepatitis C virus infection is common in patients with CKD and leads to accelerated progression to ESRD. Sofosbuvir is a potent direct-acting antiviral therapy against hepatitis C virus; however, there are concerns about its safety in patients with CKD. The objective of our study was to determine the safety and efficacy of sofosbuvir in patients with CKD. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We studied a retrospective observational cohort of patients with CKD defined by eGFR<60 ml/min per 1...
September 7, 2017: Clinical Journal of the American Society of Nephrology: CJASN
https://www.readbyqxmd.com/read/28882856/contemporary-management-of-hepatitis-c-in-patients-with-ckd
#14
EDITORIAL
Richard J Johnson, Michiko Shimada
No abstract text is available yet for this article.
September 7, 2017: Clinical Journal of the American Society of Nephrology: CJASN
https://www.readbyqxmd.com/read/28877926/effectiveness-of-quality-improvement-strategies-for-the-management-of-ckd-a-meta-analysis
#15
Samuel A Silver, Chaim M Bell, Glenn M Chertow, Prakesh S Shah, Kaveh Shojania, Ron Wald, Ziv Harel
BACKGROUND AND OBJECTIVES: Quality improvement interventions have enhanced care for other chronic illnesses, but their effectiveness for patients with CKD is unknown. We sought to determine the effects of quality improvement strategies on clinical outcomes in adult patients with nondialysis-requiring CKD. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We conducted a systematic review of randomized trials, searching Medline and the Cochrane Effective Practice and Organization of Care database from January of 2003 to April of 2015...
September 6, 2017: Clinical Journal of the American Society of Nephrology: CJASN
https://www.readbyqxmd.com/read/28855238/magnetic-resonance-elastography-to-assess-fibrosis-in-kidney-allografts
#16
Anish Kirpalani, Eyesha Hashim, General Leung, Jin K Kim, Adriana Krizova, Serge Jothy, Maya Deeb, Nan N Jiang, Lauren Glick, Gevork Mnatzakanian, Darren A Yuen
BACKGROUND AND OBJECTIVES: Fibrosis is a major cause of kidney allograft injury. Currently, the only means of assessing allograft fibrosis is by biopsy, an invasive procedure that samples <1% of the kidney. We examined whether magnetic resonance elastography, an imaging-based measure of organ stiffness, could noninvasively estimate allograft fibrosis and predict progression of allograft dysfunction. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Kidney allograft recipients >1 year post-transplant undergoing an allograft biopsy first underwent free-breathing, flow-compensated magnetic resonance elastography on a 3...
August 30, 2017: Clinical Journal of the American Society of Nephrology: CJASN
https://www.readbyqxmd.com/read/28847909/considerations-and-challenges-in-selecting-patient-reported-outcome-measures-for-clinical-trials-in-nephrology
#17
Angela Ju, Allison Tong
No abstract text is available yet for this article.
August 28, 2017: Clinical Journal of the American Society of Nephrology: CJASN
https://www.readbyqxmd.com/read/28847908/introduction-to-patient-reported-outcomes-perspectives-series
#18
Manjula Kurella Tamura
No abstract text is available yet for this article.
August 28, 2017: Clinical Journal of the American Society of Nephrology: CJASN
https://www.readbyqxmd.com/read/28847907/time-to-rethink-our-approach-to-patient-reported-outcome-measures-for-esrd
#19
Fredric O Finkelstein, Susan H Finkelstein
No abstract text is available yet for this article.
August 28, 2017: Clinical Journal of the American Society of Nephrology: CJASN
https://www.readbyqxmd.com/read/28842398/anca-glomerulonephritis-and-vasculitis
#20
J Charles Jennette, Patrick H Nachman
ANCA vasculitis has an associated autoimmune response that produces ANCAs that induce distinct pathologic lesions. Pauci-immune necrotizing and crescentic GN is a frequent component of ANCA vasculitis. ANCA vasculitis is associated with ANCA specific for myeloperoxidase (MPO-ANCA) or proteinase 3 (PR3-ANCA). A diagnosis of ANCA vasculitis should always specify the serotype as MPO-ANCA positive, PR3-ANCA positive, or ANCA-negative. To fully characterize a patient, the serotype also should be accompanied by the clinicopathologic variant if this can be determined: microscopic polyangiitis, granulomatosis with polyangiitis (Wegener), eosinophilic granulomatosis with polyangiitis (Churg-Strauss), or renal-limited vasculitis...
August 25, 2017: Clinical Journal of the American Society of Nephrology: CJASN
journal
journal
41332
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"